STOCK TITAN

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

ORMP NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
31 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+16.3% close of June 25, 2026
1-year change
+67.4% closing prices, November 14, 2025 to November 16, 2026
1-month change
-4.2% closing prices, October 16, 2026 to November 16, 2026

Company Description

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) is a clinical-stage pharmaceutical company in the pharmaceutical preparation manufacturing industry that focuses on oral delivery solutions for drugs currently delivered via injection. The company describes itself as a platform technology pioneer in this field, built around its proprietary Protein Oral Delivery (POD™) technology, which is designed to protect drug integrity and increase absorption when administered orally.

According to multiple company disclosures, Oramed’s POD™ platform underpins its work on oral formulations of injectable therapies, including a refined oral insulin program. The company has reported extensive research and development efforts to transform injectable therapies into oral medications, and has developed oral dosage forms intended to withstand the harsh environment of the stomach and deliver active biological agents such as insulin.

Business focus and technology platform

Oramed’s core business is the research and development of oral drug delivery platforms. Its POD™ technology is repeatedly described in press releases and SEC filings as a novel protein oral delivery approach that aims to maintain drug stability and improve absorption in the gastrointestinal tract. This platform is used to support the company’s oral insulin program and other potential POD™-based oral drug delivery technologies.

The company has highlighted a refined oral insulin program based on analysis of prior Phase 2 and Phase 3 clinical data. In communications to shareholders, Oramed has discussed identifying high-responder subgroups in its clinical data and designing a U.S.-based trial to further evaluate its oral insulin formulation. These activities reflect its characterization as a clinical-stage pharmaceutical company focused on advancing oral insulin and related POD™-based candidates.

Strategic transactions and investment activities

Beyond internal R&D, Oramed has developed what it calls a diversified active investment portfolio across the biomedical landscape. Company press releases and shareholder letters describe structured investments in other healthcare and biotech businesses, including Scilex Holding Company, Alpha Tau Medical Ltd., BioXcel Therapeutics Inc., Pelthos Therapeutics Inc., and other earlier-stage biotech and real estate-related positions. These investments are presented as part of a broader strategy to deploy capital in opportunities that the company believes complement its core competencies.

In relation to Scilex, Oramed has entered into a senior secured promissory note, received repayments, and negotiated royalty interests on certain Scilex products. It has also entered into warrant and option agreements regarding Scilex equity. With Alpha Tau Medical, Oramed has entered into a strategic collaboration and service agreement, providing investor and shareholder outreach, business strategic guidance, and capital markets expertise, alongside a significant equity investment and governance role through board representation. These activities illustrate how Oramed combines its drug delivery platform with capital markets and business development capabilities.

Joint ventures and platform spin-outs

Oramed has announced and explored joint venture structures to further develop and commercialize its POD™ technology. In February 2025, the company disclosed definitive agreements to spin off its POD™ technology and oral insulin assets into a new joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. (HTIT). Under those agreements, OraTech was expected to hold global marketing rights to Oramed’s POD™ oral protein delivery technology, receive capital contributions from Oramed and HTIT, and pursue Phase 3 trials and regulatory registrations for oral insulin in multiple territories.

Subsequent disclosures, however, indicate that this joint venture did not close as originally planned. In an October 2025 SEC filing, Oramed reported terminating the joint venture agreement and related supplemental agreement with HTIT after HTIT was unable to satisfy closing conditions. In later shareholder communications, Oramed stated that it planned to continue its oral insulin development program independently. These developments show how the company has adjusted its approach to partnering while maintaining its focus on oral insulin.

Strategic evolution and medical robotics exposure

In January 2026, Oramed announced binding agreements for a strategic transaction with Lifeward Ltd. (formerly ReWalk Robotics). Under this transaction, Oramed agreed to transfer its proprietary POD™ technology to Lifeward, while Oramed is expected to obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of specified conditions. Oramed also agreed to invest in Lifeward’s senior secured convertible notes with associated warrant coverage, and to manage an anticipated clinical trial under a clinical trial management agreement.

Through this transaction, Oramed describes itself as combining continued exposure to oral drug delivery innovation with participation in a revenue-generating medical robotics company. Lifeward designs, develops, and commercializes technologies such as the FDA-approved ReWalk® Personal Exoskeleton and AlterG® Anti-Gravity Systems, and Oramed has highlighted the revenue generated by these product lines in recent periods. Oramed has also disclosed that it will receive a percentage of net sales from the ReWalk franchise for a specified period. This structure positions Oramed as both a technology contributor and a significant shareholder in Lifeward.

Capital allocation, shareholder actions, and corporate governance

Oramed’s public communications emphasize its approach to capital allocation and shareholder returns. The company has discussed a stock repurchase program, cash dividends, and the potential distribution of equity in affiliated entities (such as OraTech, when that transaction was contemplated) to its shareholders. In January 2026, Oramed announced a cash dividend payment funded with surplus capital, following returns from its Scilex investment. In November 2025, the Board of Directors adopted a Rights Agreement and declared a dividend of common stock purchase rights designed, as described in the company’s press release and related SEC filing, to address potential hostile takeover scenarios and to support equal treatment of stockholders in such events.

SEC filings show that Oramed’s common stock, par value $0.012 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades under the symbol ORMP on The Nasdaq Capital Market and on the Tel Aviv Stock Exchange. The company is incorporated in Delaware. Its filings also describe corporate actions such as amendments to its stock incentive plan and the outcomes of annual stockholder meetings.

Geographic footprint

Oramed states in multiple press releases that it has offices in the United States and Israel. SEC filings list its principal executive offices in New York, New York. These disclosures indicate that the company operates across at least these two jurisdictions as it advances its clinical programs and investment activities.

Position within the pharmaceutical preparation manufacturing sector

Within the broader manufacturing sector, Oramed is classified under pharmaceutical preparation manufacturing. Its differentiation, based on its own descriptions, lies in its focus on oral delivery of drugs that are typically administered by injection, and in its use of the POD™ platform for protein and other biologic therapies. The company’s activities span clinical development, strategic partnerships, and financial investments in other biomedical and medical technology companies.

Stock Performance

$3.90
+5.12%
+0.19
Last updated: November 16, 2026 at 16:00
+67.4%
Performance 1 year
$169.6M

Oramed Pharmaceuticals (ORMP) closed at $3.90 on November 16, 2026. Over the past 12 months, the price has gained 67.4%.

See what a $1,000 investment in ORMP would be worth today

Average down calculator for ORMP

ORMP Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Oramed Pharmaceuticals has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 2 with negative movement. Key topics include management, dividends, earnings. View all ORMP news →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
50,000
Shares Sold
2
Transactions
Most Recent Transaction
Gabay Avraham (Chief Financial Officer) sold 20,000 shares @ $4.51 on October 1, 2026

Insider selling at Oramed Pharmaceuticals over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Oramed Pharmaceuticals generated $2.0M in revenue in FY2025, retaining a 0.7% gross margin, operating income reached -$15.1M, and net income was $64.0M. Diluted earnings per share stood at $1.50. The company generated -$9.1M in operating cash flow. The current ratio was 6.98, measuring current assets divided by current liabilities.

$2.0M
Revenue (FY2025)
$64.0M
Net Income (FY2025)
-$9.1M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for ORMP.

Short Interest History

Last 12 Months

Short interest in Oramed Pharmaceuticals (ORMP) currently stands at 1.3 million shares, down 7.4% from the previous reporting period, representing 4.3% of the float. Since November 2025, short interest has increased by 275.9%.

Days to Cover History

Last 12 Months

Days to cover for Oramed Pharmaceuticals (ORMP) currently stands at 11.3 days, up 9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 1034%. Across the settlements charted above, it has ranged from 1.0 to 11.3 days.

ORMP Company Profile & Sector Positioning

Oramed Pharmaceuticals (ORMP) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing ORMP often look at related companies in the same sector, including Zentalis Pharmaceuticals, Inc. (ZNTL), enGene Therapeutics Inc. (ENGN), InflaRx N.V. (IFRX), Sutro Biopharma, Inc. (STRO), and Atrium Therapeutics, Inc. (RNA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ORMP's relative position within its industry.

Frequently Asked Questions

The current stock price of Oramed Pharmaceuticals (ORMP) is $3.90 as of November 16, 2026.

The market cap of Oramed Pharmaceuticals (ORMP) is approximately $169.6M. Learn more about what market capitalization means .

The FY2025 revenue of Oramed Pharmaceuticals (ORMP) is $2.0M, from its most recent completed fiscal year.

The FY2025 net income of Oramed Pharmaceuticals (ORMP) is $64.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Oramed Pharmaceuticals (ORMP) is $1.50 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Oramed Pharmaceuticals (ORMP) is -$9.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of Oramed Pharmaceuticals (ORMP) is 0.7% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Oramed Pharmaceuticals (ORMP), current assets divided by current liabilities, was 6.98 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Oramed Pharmaceuticals (ORMP) is $13K for FY2025, its most recent completed fiscal year.

The operating income of Oramed Pharmaceuticals (ORMP) is -$15.1M for FY2025, its most recent completed fiscal year. Learn about operating income.

Oramed Pharmaceuticals’ core business is developing oral delivery solutions for drugs that are currently delivered via injection. The company describes itself as a platform technology pioneer built around its Protein Oral Delivery (POD™) technology, which is designed to protect drug integrity and increase absorption when administered orally.

Oramed’s Protein Oral Delivery (POD™) technology is a proprietary oral delivery platform for protein and other injectable drugs. Company disclosures state that it is designed to protect the integrity of the drug in the gastrointestinal tract and enhance absorption, enabling oral administration of therapies that are typically injected.

Oramed’s oral insulin program applies its POD™ technology to deliver insulin orally. The company has reported Phase 2 and Phase 3 clinical work and later focused on high-responder subgroups identified in its data. It has discussed initiating a U.S.-based trial to further evaluate its refined oral insulin formulation.

In shareholder letters and press releases, Oramed describes building a diversified active investment portfolio across the biomedical landscape. It has made structured investments in companies such as Scilex Holding Company, Alpha Tau Medical Ltd., BioXcel Therapeutics Inc., and Pelthos Therapeutics Inc., as well as in real estate-related assets, alongside its internal oral drug delivery programs.

Oramed entered into a Securities Purchase Agreement with Scilex Holding Company that included a senior secured promissory note and warrants to purchase Scilex common stock. Subsequent filings and press releases describe repayments under the note, restructuring of portions of the debt into convertible notes and warrants, and royalty interests on certain Scilex products.

In February 2025, Oramed announced definitive agreements to spin off its POD™ technology and oral insulin assets into a new joint venture, OraTech Pharmaceuticals Inc., with Hefei Tianhui Biotech Co., Ltd. Later, in an October 2025 SEC filing, Oramed reported terminating the joint venture agreement and supplemental agreement after HTIT was unable to satisfy closing conditions, and stated that it planned to continue its oral insulin program independently.

In January 2026, Oramed and Lifeward Ltd. announced binding agreements under which Oramed will transfer its POD™ technology to Lifeward. In return, Oramed is expected to obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain conditions, invest in Lifeward’s senior secured convertible notes with warrant coverage, and manage an anticipated clinical trial related to the oral delivery platform.

Oramed has announced dividend actions in its press releases. In January 2026, the company’s Board of Directors approved a cash dividend payment funded with surplus capital. The company has also discussed potential one-time dividends in connection with planned spin-offs and has declared a dividend of common stock purchase rights under a Rights Agreement.

SEC filings state that Oramed’s common stock, par value $0.012 per share, is registered under Section 12(b) of the Exchange Act and trades under the symbol ORMP on The Nasdaq Capital Market and on the Tel Aviv Stock Exchange.

Oramed’s SEC filings list its principal executive offices in New York, New York. Company press releases also state that Oramed has offices in the United States and Israel.